| 1 |
33797709 | Effectiveness of fibroblast growth factor 23 lowering modalities in chronic kidney disease: a systematic review and meta-analysis. | 2022 Feb |
2 |
| 2 |
34534708 | Hypophosphatemia after intravenous iron therapy: Comprehensive review of clinical findings and recommendations for management. | 2022 Jan |
2 |
| 3 |
34775773 | Effect of different phosphate binders on fibroblast growth factor 23 levels in patients with chronic kidney disease: a systematic review and meta-analysis of randomized controlled trials. | 2022 Apr |
1 |
| 4 |
35426179 | Osteomalacia as a Complication of Intravenous Iron Infusion: A Systematic Review of Case Reports. | 2022 Jun |
1 |
| 5 |
32743932 | Association of erythropoietin resistance and fibroblast growth factor 23 in dialysis patients: Results from the Japanese Dialysis Outcomes and Practice Patterns Study. | 2021 Jan |
1 |
| 6 |
33035687 | Fibroblast Growth Factor 23 and Exercise Capacity in Heart Failure with Preserved Ejection Fraction. | 2021 Mar |
2 |
| 7 |
33049075 | C-Terminal, but Not Intact, FGF23 and EPO Are Strongly Correlatively Elevated in Patients With Gain-of-Function Mutations in HIF2A: Clinical Evidence for EPO Regulating FGF23. | 2021 Feb |
1 |
| 8 |
33462793 | The Effect of Iron Supplementation on FGF23 in Chronic Kidney Disease Patients: a Systematic Review and Time-Response Meta-Analysis. | 2021 Dec |
7 |
| 9 |
33471363 | Parenteral iron therapy and phosphorus homeostasis: A review. | 2021 May 1 |
1 |
| 10 |
33592127 | The HIF-PHI BAY 85-3934 (Molidustat) Improves Anemia and Is Associated With Reduced Levels of Circulating FGF23 in a CKD Mouse Model. | 2021 Jun |
1 |
| 11 |
33601146 | Therapeutic potential of iron chelators on osteoporosis and their cellular mechanisms. | 2021 May |
1 |
| 12 |
33675347 | Antenatal iron supplementation, FGF23, and bone metabolism in Kenyan women and their offspring: secondary analysis of a randomized controlled trial. | 2021 May 8 |
4 |
| 13 |
33777378 | Erythropoiesis stimulating agents are associated with serum fibroblast growth factor 23 metabolism in patients on hemodialysis. | 2021 Mar |
1 |
| 14 |
33903951 | Associations among erythropoietic, iron-related, and FGF23 parameters in pediatric kidney transplant recipients. | 2021 Oct |
1 |
| 15 |
34504604 | Crosstalk of fibroblast growth factor 23 and anemia-related factors during the development and progression of CKD (Review). | 2021 Oct |
1 |
| 16 |
34757587 | Regulation of FGF23: Beyond Bone. | 2021 Dec |
1 |
| 17 |
34854600 | [Osteomalacia following intravenous iron suppletion]. | 2021 Oct 7 |
2 |
| 18 |
34901334 | Induction of FGF23-related hypophosphatemic osteomalacia by alcohol consumption. | 2021 Dec |
2 |
| 19 |
31483921 | Iron Infusion and Induced Hypophosphatemia: The Role of Fibroblast Growth Factor-23. | 2020 Jun |
2 |
| 20 |
31519999 | FGF23 at the crossroads of phosphate, iron economy and erythropoiesis. | 2020 Jan |
2 |
| 21 |
31652009 | Oral Iron Replacement Normalizes Fibroblast Growth Factor 23 in Iron-Deficient Patients With Autosomal Dominant Hypophosphatemic Rickets. | 2020 Feb |
3 |
| 22 |
31930323 | Novel use of burosumab in refractory iron-induced FGF23-mediated hypophosphataemic osteomalacia. | 2020 Aug 1 |
1 |
| 23 |
32154933 | IL-1β Drives Production of FGF-23 at the Onset of Chronic Kidney Disease in Mice. | 2020 Jul |
2 |
| 24 |
32215701 | Sharp rises in FGF23 and hypophosphatemia after intravenous iron administration do not cause myocardial damage. | 2020 Oct |
1 |
| 25 |
32236868 | FGF23: Is It Another Biomarker for Phosphate-Calcium Metabolism? | 2020 May |
1 |
| 26 |
32243649 | Fibroblast growth factor 23 mediates the association between iron deficiency and mortality in worsening heart failure. | 2020 May |
1 |
| 27 |
32452919 | Simultaneous management of disordered phosphate and iron homeostasis to correct fibroblast growth factor 23 and associated outcomes in chronic kidney disease. | 2020 Jul |
3 |
| 28 |
32476270 | Erythropoietin and a hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHDi) lowers FGF23 in a model of chronic kidney disease (CKD). | 2020 Jun |
1 |
| 29 |
32547968 | Osteomalacia and Insufficiency Fractures Secondary to Intravenous Iron Therapy: A Case Report. | 2020 |
2 |
| 30 |
32823844 | The Role of Iron and Erythropoietin in the Association of Fibroblast Growth Factor 23 with Anemia in Chronic Kidney Disease in Humans. | 2020 Aug 14 |
2 |
| 31 |
32919110 | Fibroblast growth factor 23 concentrations and modifying factors in children from age 12 to 24 months. | 2020 Dec |
2 |
| 32 |
32951052 | Intact and C-Terminal FGF23 Assays-Do Kidney Function, Inflammation, and Low Iron Influence Relationships With Outcomes? | 2020 Dec 1 |
1 |
| 33 |
33194864 | Severe Symptomatic Hypophosphataemia as a Complication of Parenteral Iron Replacement. | 2020 |
1 |
| 34 |
33392212 | Iron and Chronic Kidney Disease: Still a Challenge. | 2020 |
2 |
| 35 |
30380116 | Effect of ferric citrate on serum phosphate and fibroblast growth factor 23 among patients with nondialysis-dependent chronic kidney disease: path analyses. | 2019 Jul 1 |
1 |
| 36 |
30943476 | Differential Impacts of Intravenous Iron Administration and Iron-Containing Phosphate Binders on Serum Intact Fibroblast Growth Factor 23 Levels. | 2019 |
6 |
| 37 |
31145704 | Crosstalk between fibroblast growth factor 23, iron, erythropoietin, and inflammation in kidney disease. | 2019 Jul |
1 |
| 38 |
31218207 | Regulation of Fibroblast Growth Factor 23 by Iron, EPO, and HIF. | 2019 Mar |
3 |
| 39 |
29165637 | A controlled study of the effects of ferric carboxymaltose on bone and haematinic biomarkers in chronic kidney disease and pregnancy. | 2018 Sep 1 |
2 |
| 40 |
29181658 | Effect of ferric citrate hydrate on FGF23 and PTH levels in patients with non-dialysis-dependent chronic kidney disease with normophosphatemia and iron deficiency. | 2018 Aug |
2 |
| 41 |
29281120 | Iron Supplementation-Induced Phosphaturic Osteomalacia: FGF23 is the Culprit. | 2018 Mar |
1 |
| 42 |
29298794 | Severe FGF23-based hypophosphataemic osteomalacia due to ferric carboxymaltose administration. | 2018 Jan 3 |
1 |
| 43 |
29444509 | Associations Between Intravenous Iron, Inflammation and FGF23 in Non-Dialysis Patients with Chronic Kidney Disease Stages 3-5. | 2018 |
3 |
| 44 |
29703633 | Oral Versus Intravenous Iron Supplementation for the Treatment of Iron Deficiency Anemia in Patients on Maintenance Hemodialysis-Effect on Fibroblast Growth Factor-23 Metabolism. | 2018 Jul |
10 |
| 45 |
29740119 | Circulating Fibroblast Growth Factor-23 Levels are Associated with an Increased Risk of Anemia Development in Patients with Nondialysis Chronic Kidney Disease. | 2018 May 8 |
1 |
| 46 |
29874654 | Ferric Citrate Decreases Fibroblast Growth Factor 23 and Improves Erythropoietin Responsiveness in Hemodialysis Patients. | 2018 |
1 |
| 47 |
30218014 | Role of phosphate sensing in bone and mineral metabolism. | 2018 Nov |
1 |
| 48 |
30353318 | Non-renal-Related Mechanisms of FGF23 Pathophysiology. | 2018 Dec |
1 |
| 49 |
27558654 | Oral iron supplementation with sodium ferrous citrate reduces the serum intact and c-terminal fibroblast growth factor 23 levels of maintenance haemodialysis patients. | 2017 Dec |
3 |
| 50 |
27659127 | Fibroblast growth factor 23 actions in inflammation: a key factor in CKD outcomes. | 2017 Sep 1 |
1 |